Edmonton, Alberta, Canada
December 4, 2008
Innovotech Inc.
("Innovotech" and/or the "Company") (TSX VENTURE:IOT) is pleased
to announce the results of its 2008 Field Trials for its new
seed treatment, Agress™. Innovotech tested Agress™ against
bacterial bean blight on dry beans, peas and soybeans in
Alberta, Saskatchewan and Manitoba in replicated small plot
studies.
"The results from the study clearly demonstrate that Agress™
performs at least as well as, and in some cases far superior to
Agricultural Streptomycin in providing disease control in the
pulse crops tested," says Damian Sowa, Product Manager,
Innovotech. "It is well known that governments around the world
have concerns regarding Agricultural Streptomycin because of the
build-up of bacterial resistance. Our studies have shown that
Agress™ can an effective replacement for Streptomycin.
Innovotech has already initiated studies of other plant diseases
such as fire blight, where the use of Agricultural Streptomycin
is currently the product of choice."
Innovotech anticipates regulatory approval for Agress™ in Canada
and the United States in mid to late 2009, permitting product
availability for the 2010 crop season. Research is currently
underway to expand the claims of Agress™ to major crops in North
America and additional disease classes.
Innovotech is a product development company focusing on the
development of solutions to medical, agricultural and industrial
problems caused by microbial biofilms. Biofilms are protected
communities of microorganisms which are very common and very
difficult to treat due to their inherent resistance. They have
been implicated in a host of devastating infections in
agriculture, human health and industry. No diagnostics or
antibiotics are currently approved for use in infections
involving biofilms. |
|
